Juvenile Arthritis | Overview
Tremfya Clinical Trial
What is the goal of the study? This study is looking to gain approval for Tremfya, a drug currently used to treat adults with psoriatic arthritis, for use in children with active psoriatic arthritis.
How do you participate? This study is open to patients with psoriatic arthritis who are between ages 5-17 (inclusive) with active disease in at least 3 joints. If you join the study, you will receive treatment with Tremfya for at least one year. This medication is given via injection either every 4 weeks or every 8 weeks. You will be asked to come in for a study visit every 4 weeks while in the study for check-ups, and we will also collect blood samples to see how the medication is working. If you have any questions, please contact our research team.
Email: RheumResearchTeam@childrens.harvard.edu
BACK-OFF jSpA Study
What is the goal of the study? This study is looking to determine which patients with juvenile spondyloarthritis can come off of their medications or lower the dose of their medications safely and without a flare of their arthritis.
How do you participate? This study is open to patients with juvenile spondyloarthritis and who are 8-21 years old (inclusive). You must be in remission (without active disease) and taking the standard dose of a TNF inhibitor to treat your arthritis. Patients who join the study will be randomly assigned to either continue their treatment, decrease the dose of their treatment, or stop their treatment completely. We will ask you to follow that assignment for one year and come in for a rheumatology visit every three months during that time. We may also collect blood samples if you give permission when joining the study. If you have any questions, please contact our research team.